8:55 am Chair’s Opening Remarks

Exciting Approaches to Tackling the Unmet Needs of the Dermatology Universe

9:00 am Utilising Selective TRPV3 Inhibitors as Novel Treatments for Rare Dermatological Diseases & Itch


  • Diving into Kamari Pharma’s pipeline of topical and oral TRPV3 inhibitors
  • Detailing the success of TRPV3 inhibitors at normalising skin structure and function and significantly reducing pathological outcomes
  • Review of current clinical trials ongoing with this topical treatment for Keratodermas in Israel and the UK

9:30 am What’s Next for Hidradenitis Suppurativa, New Opportunities, New Endpoints, New Beginnings


  • Discussing the current HS landscape
  • Learning new ways to develop better treatments across dermatology and immunology
  • An opportunity to challenge and be challenged by peers building networking connections

10:00 am Examining the Therapeutic & Commercial Potential of Multi-Target Therapeutics in Atopic Dermatitis & Epidermolysis Bullosa

  • Neal Koller Chief Executive Officer, Alphyn Biologics, LLC


  • Utilising multiple mechanisms of action; anti-inflammatory, anti-itch and antibacterial and evidence to support this mechanism
  • Exploring the bacterial component of Atopic Dermatitis and Epidermolysis Bullosa.
  • Detailing the safety profile of AB101-a for AD.

10:30 am Morning Break

11:30 am Virtual Presentation: Examining the Potential of Topical Soft MEK Inhibitors for Rare Dermatological Disorders


  • Detailing the discovery and development of a metabolically liable topical MEK inhibitor
  • Utilising MEK Inhibitors for cutaneous neurofibromas in neurofibromatosis type 1
  • Nflection Therapeutics next steps in rare dermatological diseases

12:00 pm A New Role of Complement C5a Signalling in Immunodermatology: First Results from a Dose-Escalation Study in Pyoderma Gangreanosum

  • Hoda Tawfik Vice President, Program Head Dermatology & Oncology, Inflarx N. V.


  • Discussing InflaRx approach linking Complement signaling with treatments in Immunodermatology
  • Rationale behind C5a inhibition for Pyoderma Gangraenosum
  • Promising results from a dose-escalation study for vilobelimab, a first-in-class monoclonal antibody targeting C5a

Exploring Optimal Formulation & Effective Drug Delivery in Dermatology

12:30 pm Panel Discussion: Roundtable Discussion


This interactive session gives you the opportunity to be part of the discussion, share ideas and learn from your peers. Choose the table most relevant to you, and get ready to be part of this conversation:

  • Discuss current shortfalls in dermatological drug development to identify mechanisms to overcome these challenge
  • Explore a range of current and future drug delivery methods and discuss important considerations when treating hyperkeratotic skin
  • Debate optimal dosing strategies Topical vs Oral vs Intravenous, explore your colleagues preferences and reasons why

Closing this session with feedback from each break away group on effective drug delivery and the most

valuable dosing strategy.

1:00 pm Lunch Break

Looking Forward & Identifying Next Steps Within Dermatological Drug Development

2:00 pm Virtual Presentation: Detailing the Success of OX40 Pathway Inhibition & its Promise in Other Dermatological Conditions

  • Primal Kaur Vice President Global Development, Amgen Inc.


  • Discussing the success of OX40 inhibition in Atopic Dermatitis
  • Understanding the benefits of OX40 inhibition
  • How we can utilise this success in Lupus 

2:30 pm Virtual Presentation: Using Clinical Phenotyping to Direct Therapy of Genetic Skin Disorders

  • Edel O’Toole Professor of Molecular Dermatology /Consultant Dermatologist, Queen Mary University Of London


  • Filaggrin and its role in various dermatological diseases including keratodermas
  • Discussing various phenotypes of palmoplantar keratodermas
  • Highlighting the promise of common pathomechanism to be targeted with a single therapeutic

3:00 pm Chair’s Closing Remarks